Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease

Claude M Wischik, Richard Stefanacci, Peter Bentham, Serge Gauthier, Henrik Zetterberg, Gordon K Wilcock, Lutz Froelich, Alistair Burns, Emer MacSweeney, Clive Ballard, Jin-Tai Yu, Tay Siew Choon, Vahe Asvatourian, Natalia Muehlemann, Jan Priel, Karin Kook, Tenecia Sullivan, Diane Downie, Sonya Miller, Carol Pringle, John M. D Storey, Tom Baddeley, Charles R Harrington, Lewis K Penny, Mohammad Arastoo, Roger Staff, Anca-Larisa Sandu, Helen Shiells, Serena Lo, Nafeesa Nazlee, Emily Evans, Claire Hull, Bjoern O Schelter

Open source

DOI: 10.1016/j.tjpad.2026.100480
Published: 2026-03
Container: The Journal of Prevention of Alzheimer's Disease
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.tjpad.2026.100480,
  title = {Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease},
  author = {Claude M Wischik and Richard Stefanacci and Peter Bentham and Serge Gauthier and Henrik Zetterberg and Gordon K Wilcock and Lutz Froelich and Alistair Burns and Emer MacSweeney and Clive Ballard and Jin-Tai Yu and Tay Siew Choon and Vahe Asvatourian and Natalia Muehlemann and Jan Priel and Karin Kook and Tenecia Sullivan and Diane Downie and Sonya Miller and Carol Pringle and John M. D Storey and Tom Baddeley and Charles R Harrington and Lewis K Penny and Mohammad Arastoo and Roger Staff and Anca-Larisa Sandu and Helen Shiells and Serena Lo and Nafeesa Nazlee and Emily Evans and Claire Hull and Bjoern O Schelter},
  year = {2026},
  journal = {The Journal of Prevention of Alzheimer's Disease},
  doi = {10.1016/j.tjpad.2026.100480},
  url = {https://doi.org/10.1016/j.tjpad.2026.100480}
}

RIS

TY  - JOUR
TI  - Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease
AU  - Claude M Wischik
AU  - Richard Stefanacci
AU  - Peter Bentham
AU  - Serge Gauthier
AU  - Henrik Zetterberg
AU  - Gordon K Wilcock
AU  - Lutz Froelich
AU  - Alistair Burns
AU  - Emer MacSweeney
AU  - Clive Ballard
AU  - Jin-Tai Yu
AU  - Tay Siew Choon
AU  - Vahe Asvatourian
AU  - Natalia Muehlemann
AU  - Jan Priel
AU  - Karin Kook
AU  - Tenecia Sullivan
AU  - Diane Downie
AU  - Sonya Miller
AU  - Carol Pringle
AU  - John M. D Storey
AU  - Tom Baddeley
AU  - Charles R Harrington
AU  - Lewis K Penny
AU  - Mohammad Arastoo
AU  - Roger Staff
AU  - Anca-Larisa Sandu
AU  - Helen Shiells
AU  - Serena Lo
AU  - Nafeesa Nazlee
AU  - Emily Evans
AU  - Claire Hull
AU  - Bjoern O Schelter
PY  - 2026
JO  - The Journal of Prevention of Alzheimer's Disease
DO  - 10.1016/j.tjpad.2026.100480
UR  - https://doi.org/10.1016/j.tjpad.2026.100480
ER  -

APA

Wischik, C. M., Stefanacci, R., Bentham, P., Gauthier, S., Zetterberg, H., Wilcock, G. K., Froelich, L., Burns, A., MacSweeney, E., Ballard, C., Yu, J., Choon, T. S., Asvatourian, V., Muehlemann, N., Priel, J., Kook, K., Sullivan, T., Downie, D., Miller, S., Pringle, C., Storey, J. M. D., Baddeley, T., Harrington, C. R., Penny, L. K., Arastoo, M., Staff, R., Sandu, A., Shiells, H., Lo, S., Nazlee, N., Evans, E., Hull, C., & Schelter, B. O. (2026). Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease. The Journal of Prevention of Alzheimer's Disease. https://doi.org/10.1016/j.tjpad.2026.100480

Source records

crossref · retrieved 2026-09-27T02:05:26.756Z